Login to Your Account

Meditope Nabs $3.6M to Turn MAbs into 'Legos'

By Marie Powers
Staff Writer

Monday, July 29, 2013

Start-up Meditope Biosciences Inc. tucked $3.6 million under its belt in a Series A funded by angel investors to advance its monoclonal antibody (MAb) linker technology. The Los Angeles-based biotech is advancing cancer therapeutics discovered at City of Hope, a National Cancer Institute-designated Comprehensive Cancer Center in Duarte, Calif.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription